Bai Li Tian Heng's wholly-owned subsidiary and Bai Shi Mei Shi Gui Bao have reached a cooperation agreement on BL-B01D1
Le174
发表于 2023-12-12 11:09:00
1291
0
0
Baili Tianheng disclosed on the morning of December 12th that its wholly-owned subsidiary SystImmune, Inc (hereinafter referred to as "SystImmune") and Bristol Myers Squibb (hereinafter referred to as "BMS", New York Stock Exchange code: BMY) reached a global strategic cooperation agreement on December 11 regarding the development and commercialization rights of BL-B01D1, with a potential total transaction amount of up to $8.4 billion.
The announcement shows that SystImmune and BMS are in contact with BL-B01D1 (EGFR) × The HER3 dual antibody ADC project has reached an exclusive licensing and cooperation agreement. BL-B01D1 is a potential first of its kind EGFR/HER3 bispecific antibody drug conjugate (ADC). According to the cooperation agreement, both parties will cooperate to promote the development and commercialization of BL-B01D1 in the United States. SystImmune will be solely responsible for the development, commercialization and production of BL-B01D1 in Chinese Mainland through its affiliated companies, as well as the production of some drugs for use outside Chinese Mainland. BMS will be exclusively responsible for the development and commercialization of BL-B01D1 in other regions around the world.
After the cooperation agreement takes effect, BMS will make a down payment of $800 million to SystImmune, as well as up to $500 million in recent contingent payments; After achieving development, registration, and sales milestones, SystImmune will receive an additional payment of up to $7.1 billion; The potential total transaction volume can reach up to $8.4 billion. The milestone payment stipulated in the cooperation agreement needs to meet certain conditions, and there is still uncertainty in the final milestone payment.
BL-B01D1 is an ADC based on bispecific topoisomerase inhibitors that can target both epidermal growth factor receptor and human epidermal growth factor receptor 3 (EGFR) simultaneously × HER3). We are currently conducting a global multicenter Phase I clinical study (BL-B01D1-LUNG101) to evaluate its safety and efficacy in patients with metastatic or unresectable non-small cell lung cancer (NSCLC). The early clinical research data of BL-B01D1 have been announced at the 2023 American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO) and San Antonio breast cancer Seminar (SABCS). These data show that BL-B01D1 shows promising anti-tumor activity in patients with non-small cell lung cancer and breast cancer who have progressed after standard treatment.
According to the information on Baili Tianheng's WeChat official account on the 12th, Zhu Yi, chairman and general manager of the company and chief executive of SystImmune, said, "This strategic cooperation is an important step to provide potential anti-tumor drugs to patients around the world, and we look forward to active and fruitful cooperation." Samit Hirawat, Chief Medical Officer and Head of Drug Development, said, "SystImmune's BL-B01D1 adds an ADC to our diversified research and development pipeline, which aligns well with our strategy of providing the most suitable treatment model for unmet solid tumor treatment needs. We look forward to working with SystImmune to make BL-B01D1 a differentiated treatment choice for patients in need."
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Ericsson and Swiss Telecom will sign a multi-year cooperation agreement
- JD and Xiaomi sign a strategic cooperation agreement
- SAP and Tang Renshen sign a strategic cooperation agreement
- Jointly exploring innovative insurance e-commerce models, Huize and Xinhua Insurance sign strategic cooperation agreement
- Huizhe and Xinhua Insurance signed a strategic cooperation agreement in Shenzhen
- Jointly exploring innovative insurance e-commerce models, Huize and Xinhua Insurance sign strategic cooperation agreement in Shenzhen
- NIO and Sinopec reach charging service cooperation agreement
- NIO and Sinopec reach charging service cooperation agreement
- NIO Energy and Wuhan Shouyi Science and Technology Innovation Investment signed a cooperation agreement
- NIO Energy and Wuhan Shouyi Science and Technology Innovation Investment signed a cooperation agreement
-
苹果知名分析师郭明錤周四(10月31日)在社交媒体上发文表示,苹果明年可能会减少对芯片制造商博通Wi-Fi芯片的依赖,并推出自己的处理器。 郭明錤在社交媒体平台X上写道,“在2025年下半年的新产品(例如iPh ...
- uturn
- 昨天 14:42
- 支持
- 反对
- 回复
- 收藏
-
10月30日,小鹏汽车生态企业小鹏汇天宣布,旗下分体式飞行汽车“陆地航母”即将亮相2024中国航展,11月12日将在中国航展第二展区(斗门莲洲)进行全球首次公开飞行,同时“陆地航母”也将在珠海国际航展中心8号 ...
- yxtianyouyou
- 前天 11:43
- 支持
- 反对
- 回复
- 收藏
-
交易所监管文件显示,当地时间11月1日,亚马逊创始人杰夫·贝索斯拟出售约1635万股亚马逊股票,预计套现约30.5亿美元。今年7月,贝索斯已申请额外出售约2500万股亚马逊股票,按当时股价计算可套现约50亿美元。 ...
- blueskybb
- 12 小时前
- 支持
- 反对
- 回复
- 收藏
-
近日,凯撒海湾目的地(山东)运营管理有限责任公司(简称“凯撒海湾”)与携程旅悦集团签署战略合作协议,双方将围绕“海上目的地运营”、“旅游产品与服务创新”、“研学旅行”、“日韩及海外旅游市场开拓”等 ...
- llyyy2008
- 11 小时前
- 支持
- 反对
- 回复
- 收藏